These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1979729)

  • 61. Reduction of beta-adrenergic receptors can explain the lack of rebound effect after tertatolol withdrawal.
    De Blasi A; Pittana PL; Fratelli M; Garattini S
    Am J Hypertens; 1989 Nov; 2(11 Pt 2):257S-260S. PubMed ID: 2573373
    [TBL] [Abstract][Full Text] [Related]  

  • 62. European experience with artex: the Tertatolol International Multicentre Study (TIMS).
    Laher MS
    Cardiology; 1993; 83 Suppl 1():25-31. PubMed ID: 7903212
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison between short-term renal haemodynamic effects of propranolol and nadolol in essential hypertension: a cross-over study.
    Danesh BJ; Brunton J; Sumner DJ
    Clin Sci (Lond); 1984 Aug; 67(2):243-8. PubMed ID: 6146425
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of tertatolol, a beta-adrenoceptor antagonist with agonist affinity at 5-HT1A receptors, in an animal model of migraine: comparison with propranolol and pindolol.
    Saxena PR; Heiligers JP; Villalón CM; Ferrari MD
    Eur J Pharmacol; 1992 Sep; 220(1):79-86. PubMed ID: 1358648
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Overview of clinical safety and efficacy of tertatolol.
    Vivet P
    Cardiology; 1993; 83 Suppl 1():41-50. PubMed ID: 7903214
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Acute renal effects of oral felodipine in normal man.
    Schmitz A
    Eur J Clin Pharmacol; 1987; 32(1):17-22. PubMed ID: 3582465
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tertatolol in hypertension. Long-term therapy in 2,338 patients.
    Guery O; Herpin D; Lecasble M; Piron J
    Am J Hypertens; 1989 Nov; 2(11 Pt 2):289S-295S. PubMed ID: 2573378
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function.
    Dupont AG; Vanderniepen P; Bossuyt AM; Jonckheer MH; Six RO
    Br J Clin Pharmacol; 1985 Aug; 20(2):93-9. PubMed ID: 2864051
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Tertatolol in chronic renal failure. A pharmacokinetic study.
    Rainfray M; Rocher I; Mignon F; Meyrier A
    Am J Hypertens; 1989 Nov; 2(11 Pt 2):266S-277S. PubMed ID: 2573374
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Tertatolol does not affect biochemical markers of atherosclerosis in normo- and hyperlipidemic hypertensive patients.
    Richard JL; Martin C; Jacotot B
    Am J Nephrol; 1986; 6 Suppl 2():100-5. PubMed ID: 2879464
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Recent advances in beta blockade. Therapeutic implications in hypertension. Proceedings of the First International Symposium on Tertatolol, 15th June, 1985, Milano, Italy.
    Am J Nephrol; 1986; 6 Suppl 2():1-116. PubMed ID: 2879463
    [No Abstract]   [Full Text] [Related]  

  • 72. Effects of tertatolol on glomerular mesangial cells.
    Shultz PJ; Raij L
    J Hypertens Suppl; 1991 Dec; 9(6):S358-9. PubMed ID: 1687872
    [No Abstract]   [Full Text] [Related]  

  • 73. Acute changes in renal function induced by bisoprolol, a new cardioselective beta-blocking agent.
    Glück Z; Reubi FC
    Eur J Clin Pharmacol; 1986; 31(1):107-11. PubMed ID: 2877882
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tertatolol: a beta-blocker with unique effects on human glomerular cell function.
    Shultz P; Raij L
    Cardiology; 1993; 83 Suppl 1():51-6. PubMed ID: 7903216
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Beta-adrenergic receptor changes during tertatolol treatment in healthy volunteers: relevance for beta-blocking therapy.
    De Blasi A; Lipartiti M; Garattini S
    Am J Nephrol; 1986; 6 Suppl 2():69-73. PubMed ID: 2879475
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Renal effects of nicardipine in essential hypertension: differences between acute and chronic therapy.
    Smith SA; Rafiqi EI; Gardener EG; Young MA; Littler WA
    J Hypertens; 1987 Dec; 5(6):693-7. PubMed ID: 3429869
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Tertatolol potentiates exercise-induced atrial natriuretic peptide release by increasing atrial diameter in healthy subjects.
    Berlin I; Deray G; Lechat P; Maistre G; Landault C; Chermat V; Brouard R; Ressayre C; Puech AJ
    Cardiology; 1993; 83 Suppl 1():16-24. PubMed ID: 7903211
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Responses of glomerular filtration, renal blood flow and salt-water handling to acute cardioselective and non-selective beta-adrenoceptor blockade in essential hypertension.
    Koch G; Fransson L; Karlegärd L; Kothari P
    Eur J Clin Pharmacol; 1989; 36(4):343-5. PubMed ID: 2567670
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The effects of tertatolol on lipid profile.
    Diehm C; Jacobsen O; Amendt K
    Cardiology; 1993; 83 Suppl 1():32-40. PubMed ID: 7903213
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dynamic renal function testing by compartmental analysis: assessment of renal functional reserve in essential hypertension.
    Zitta S; Stoschitzky K; Zweiker R; Oettl K; Reibnegger G; Holzer H; Estelberger W
    Nephrol Dial Transplant; 2000 Aug; 15(8):1162-9. PubMed ID: 10910439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.